An official website of the United States government
Home
Name
KRd
Alternate names
KRD
Primary Site
None
Histology
Multiple myeloma
Radiation
None
Remarks
July 2020 KRd - carfilzomib (Kyprolis) -- chemotherapy, lenalidomide (Revlimid) -- BRM, and dexamethasone -- hormone is a new treatment for newly treated patients with standard- and intermediate-risk multiple myeloma who are not slated for immediate autologous stem cell transplantation (ASCT).
8/12/2025 update: code all three agents
8/12/2025 update: code all three agents
Drugs for KRd
Name
Alternate Names
Kyprolis
Abbreviations
None
Category
Chemotherapy
Subcategory
Proteasome inhibitor
NSC Number
None
Primary Site
Multiple myeloma
Histology
None
Remarks
September 4, 2020: FDA has approved Kyprolis (carfilzomib) and Darzalex (daratumumab) in combination with dexamethasone for adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy.
July 20, 2012 the FDA approved Kyprolis under the accelerated approval program for the treatment of multiple myeloma.
July 20, 2012 the FDA approved Kyprolis under the accelerated approval program for the treatment of multiple myeloma.
Coding
This drug should be coded
Name
Alternate Names
Revlimid
lenalidomide
Abbreviations
None
Category
Biologic therapy (BRM, immunotherapy)
Subcategory
Cytostatic agent--antiangiogenesis agent
NSC Number
703813
Primary Site
5q- MDS
CLL
MDS
Multiple myeloma
melanoma
Lymphoma
Histology
None
Remarks
May 28, 2019: FDA approved lenalidomide (REVLIMID) in combination with a rituximab product for previously treated follicular lymphoma (FL) and previously treated marginal zone lymphoma (MZL).
2/22/2017: FDA approved lenalidomide (Revlimid) as maintenance therapy for patients with multiple myeloma following autologous stem cell transplant.
July 2013 UPDATE: Revlimid received FDA approval for use in the treatment of mantle cell lymphoma (MCL) whose disease has relapsed after two prior therapies, one of which included bortezomib.
FDA approved for MDS 2005, for multiple myeloma 2006, orphan drug status CLL
Thalidomide analog immunomodulatory derivative.
February 20, 2015 update: FDA approved revlimid given in combination with dexamethasone as first course treatment for newly diagnosed multiple myeloma.
2/22/2017: FDA approved lenalidomide (Revlimid) as maintenance therapy for patients with multiple myeloma following autologous stem cell transplant.
July 2013 UPDATE: Revlimid received FDA approval for use in the treatment of mantle cell lymphoma (MCL) whose disease has relapsed after two prior therapies, one of which included bortezomib.
FDA approved for MDS 2005, for multiple myeloma 2006, orphan drug status CLL
Thalidomide analog immunomodulatory derivative.
February 20, 2015 update: FDA approved revlimid given in combination with dexamethasone as first course treatment for newly diagnosed multiple myeloma.
Coding
This drug should be coded
Name
Alternate Names
Aeroseb-Dex
AK-Dex
AK-Trol
Baldex
Component of Deronil
Component of Dexacidin
Component of Maxitrol
Dalalone
Decaderm
Decadrol
Decadron Tablets
Decajet
Decameth
Decasone
Decaspray
Deenar
Dex-4
Dexacen
Dexacidin
Dexacort Phosphate
Dexameth
Dexasone
Dexasporin
Dexone
Dexsone
Dezone
Gammacorten
Hexadrol
Hexadrol Elixir
Hexadrol Tablets
Infectrol Sterile
Maxidex
Maxitrol
Miral
Mymethasone
Neo-Dexameth
Neodecadron
Neodexair
Ocu-Trol
Oradexon
PMS-Dexamethasone Sodium Phosphate
SK-Dexamethasone
Sofracort
Sofradex
Solurex
Spersadex
Sterile Dexamethasone Acetate
Tobradex
Turbinare Decaron Phosphate
Abbreviations
DECA
DM
DSM
Category
Ancillary Agent
Hormones and hormonal mechanisms
Subcategory
Glucocorticoid. Probably not cancer directed--verify with attending MD.
NSC Number
345211
Primary Site
None
Histology
None
Remarks
NOTE* Dexamethasone may be coded as either an ancillary drug or hormone. Review chart to determine if given for supportive care or as hormonal therapy.
A long-acting corticosteroid (glucocorticoid). In general, this drug is used more commonly for supportive care, and as an antiemetic than it is as hormone therapy. 25 times as potent as cortisol; used topically as an anti-inflammatory and administered orally in replacement therapy for adrenal insufficiency, as an anti-inflammatory and immunosuppressant in a wide variety of disorders, and as an antiemetic in cancer chemotherapy. Dexamethasone and other corticosteroids may be used to control white cell proliferation in hematopoietic diseases and would be coded as hormone therapy for leukemia, lymphoma and multiple myeloma.
A long-acting corticosteroid (glucocorticoid). In general, this drug is used more commonly for supportive care, and as an antiemetic than it is as hormone therapy. 25 times as potent as cortisol; used topically as an anti-inflammatory and administered orally in replacement therapy for adrenal insufficiency, as an anti-inflammatory and immunosuppressant in a wide variety of disorders, and as an antiemetic in cancer chemotherapy. Dexamethasone and other corticosteroids may be used to control white cell proliferation in hematopoietic diseases and would be coded as hormone therapy for leukemia, lymphoma and multiple myeloma.
Coding
Please see remarks for additional information
